The method according to claim 1 or 2, the use according to any one of claims 3-6, or the composition according to claim 7 or 8, wherein the subject is a subject which has been identified as being a responder to treatment with the composition
In addition, mitoglitazone significantly alleviates renal I/R injury in mice by upregulating GPX4 and reducing iron-related lipid peroxidation
N Engl J Med 392(6):612615 [DOI] [PubMed] [Google Scholar] 28.Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T (2023) Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
This panel illustrates a dual-pathway model for semaglutide hepatic benefits and reduction of overall target-organ risk in patients with cardiometabolic compromise: a weight-dependent pathway (primary driver), and a weight-independent or partially independent pathway, supported by reductions in HbA1c, systolic blood pressure, and hs-CRP
